Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels

被引:101
作者
Bossard, Celine [1 ]
Dobay, Maria Pamela [2 ]
Parrens, Marie [3 ]
Lamant, Laurence [4 ]
Missiaglia, Edoardo [2 ]
Haioun, Corinne [5 ]
Martin, Antoine [6 ]
Fabiani, Bettina [7 ]
Delarue, Richard [8 ]
Tournilhac, Olivier [9 ]
Delorenzi, Mauro [2 ,10 ,11 ]
Gaulard, Philippe [12 ,13 ,14 ]
de Leval, Laurence [15 ]
机构
[1] Hop Hotel Dieu, Ctr Hosp Univ, Serv Anat & Cytol Pathol, Nantes, France
[2] Swiss Inst Bioinformat, Lausanne, Switzerland
[3] Hop Pessac, Dept Pathol, Bordeaux, France
[4] Hop Purpan, Dept Pathol, Toulouse, France
[5] AP HP, Grp Henri Mondor Albert Chenevier, Unite Hemopathies Lymphoides, Creteil, France
[6] Hop Avicenne, Serv Anat & Cytol Pathol, F-93009 Bobigny, France
[7] Hop St Antoine, AP HP, Dept Anat Pathol, F-75571 Paris, France
[8] Hop Necker Enfants Malad, AP HP, Hematol Serv, Paris, France
[9] Univ Auvergne, Inserm Ctr Invest Clin 501, Ctr Hosp Univ Clermont Ferrand Hop Estaing, Serv Therapie Cellulaire & Hematol Clin Adulte, Clermont Ferrand, France
[10] Univ Lausanne, Ludwig Ctr Canc Res, Lausanne, Switzerland
[11] Univ Lausanne, Dept Oncol, Lausanne, Switzerland
[12] AP HP, Grp Henri Mondor Albert Chenevier, Dept Pathol, Creteil, France
[13] Inserm U955, Creteil, France
[14] Univ Paris Est, Creteil, France
[15] CHU Vaudois, Inst Pathol, CH-1011 Lausanne, Switzerland
关键词
BRENTUXIMAB VEDOTIN; PHASE-II; PROJECT; FEATURES; RECEPTOR; SUBTYPES; NASAL; ALCL;
D O I
10.1182/blood-2014-07-584953
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA(mRNA) assessment by microarrays in a cohort of 376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs.
引用
收藏
页码:2983 / 2986
页数:4
相关论文
共 24 条
  • [1] [Anonymous], WHO CLASSIFICATION T
  • [2] Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
    Au, Wing-yan
    Weisenburger, Dennis D.
    Intragumtornchai, Tanin
    Nakamura, Shigeo
    Kim, Won-Seog
    Sng, Ivy
    Vose, Julie
    Armitage, James O.
    Liang, Raymond
    [J]. BLOOD, 2009, 113 (17) : 3931 - 3937
  • [3] A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas
    Bartlett, Nancy L.
    Sharman, Jeff P.
    Oki, Yasuhiro
    Advani, Ranjana H.
    Bello, Celeste M.
    Winter, Jane N.
    Yang, Yin
    Kennedy, Dana A.
    Jacobsen, Eric D.
    [J]. BLOOD, 2013, 122 (21)
  • [4] The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells
    de Leval, Laurence
    Rickman, David S.
    Thielen, Caroline
    de Reynies, Aurelien
    Huang, Yen-Lin
    Delsol, Georges
    Lamant, Laurence
    Leroy, Karen
    Briere, Josette
    Molina, Thierry
    Berger, Francoise
    Gisselbrecht, Christian
    Xerri, Luc
    Gaulard, Philippe
    [J]. BLOOD, 2007, 109 (11) : 4952 - 4963
  • [5] Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project
    Delabie, Jan
    Holte, Harald
    Vose, Julie M.
    Ullrich, Fred
    Jaffe, Elaine S.
    Savage, Kerry J.
    Connors, Joseph M.
    Rimsza, Lisa
    Harris, Nancy L.
    Mueller-Hermelink, Konrad
    Ruediger, Thomas
    Coiffier, Bertrand
    Gascoyne, Randy D.
    Berger, Francoise
    Tobinai, Kensei
    Au, Wing Y.
    Liang, Raymond
    Montserrat, Emili
    Hochberg, Ephraim P.
    Pileri, Stefano
    Federico, Massimo
    Nathwani, Bharat
    Armitage, James O.
    Weisenburger, Dennis D.
    [J]. BLOOD, 2011, 118 (01) : 148 - 155
  • [6] Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes
    Deleeuw, Ronald J.
    Zettl, Andreas
    Klinker, Erdwine
    Haralambieva, Eugenia
    Trottier, Magan
    Chari, Raj
    Ge, Yong
    Gascoyne, Randy D.
    Chott, Andreas
    Muller-Hermelink, Hans-Konrad
    Lam, Wan L.
    [J]. GASTROENTEROLOGY, 2007, 132 (05) : 1902 - 1911
  • [7] Delsol G., 2008, WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, P312
  • [8] MOLECULAR-CLONING AND EXPRESSION OF A NEW MEMBER OF THE NERVE GROWTH-FACTOR RECEPTOR FAMILY THAT IS CHARACTERISTIC FOR HODGKINS-DISEASE
    DURKOP, H
    LATZA, U
    HUMMEL, M
    EITELBACH, F
    SEED, B
    STEIN, H
    [J]. CELL, 1992, 68 (03) : 421 - 427
  • [9] FALINI B, 1995, BLOOD, V85, P1
  • [10] Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+Mature T- and NK-Cell Lymphomas
    Fanale, Michelle A.
    Horwitz, Steven M.
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Advani, Ranjana H.
    Pro, Barbara
    Chen, Robert
    Davies, Andrew
    Illidge, Tim
    Huebner, Dirk
    Kennedy, Dana A.
    Shustov, Andrei R.
    [J]. BLOOD, 2013, 122 (21) : 4386 - 4386